Skip to main content
Explore URMC
menu

Kevin Charles Bylund, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-8762

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Radiation Oncology

Biography

While in training, I found great fulfillment in caring for patients with cancer, seeing their strength and resolve and trying to match this in my determination to give them the best possible treatment.

I was particularly attracted to radiation oncology due to my background in physics and the multitude of options radiation provides to treat patients with cancer. I have special interests in brachytherapy (low-dose and high-dose rates), as well as the protection of normal tissue during radiation therapy.

Since I believe all patients have unique stories to tell, my goal is to understand their individual stories – and then to discuss and tailor their radiation and cancer care. I love my work and feel privileged to support patients during the very difficult – and often rewarding – time of cancer treatment and follow-up.

Conditions I Treat

- Genitourinary cancers (prostate, bladder, kidney, testicular, etc.)
- Gynecologic cancers (endometrial, cervical, etc.)
- General radiation oncology

Credentials

Specialties

  • Radiation Oncology - American Board of Radiology

Education

2008
MD | University of Rochester School of Medicine & Dentistry

Post-doctoral Training & Residency

07/01/2009 - 06/30/2013
Residency in Radiation Oncology at University of Rochester Medical Center

07/01/2008 - 06/30/2009
Internship in Internal Medicine at Saint Louis University

Awards

2015
Educator of the Year
Sponsor: Association of Residents in Radiation Oncology

2012
RSNA Roentgen Resident/Fellow Research Award
Sponsor: University of Rochester
Location: Rochester, NY

2008
RSNA Roentgen Resident/Fellow Research Award
Sponsor: University of Iowa
Location: Iowa City, IA

VIEW ALL expand_more

Clinical Trials

Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

Lead Researcher: Kevin Charles Bylund

This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving a shorter hormone therapy treatment may work the same at controlling prostate cancer compared to the usual 24 month hormone therapy treatment in patients with low gene risk score. Adding apalutamide to the usual treatment may increase the length of time without prostate cancer spreading as compared to the usual treatment in patients with high gene risk score.

View Study Details

Publications

Journal Articles

2022
Kerns SL; Amidon Morlang A; Lee SM; Peterson DR; Marples B; Zhang H; Bylund K; Rosenzweig D; Hall W; De Ruyck K; Rosenstein BS; Stock RG; Gómez-Caamaño A; Vega A; Sosa-Fajardo P; Taboada-Valladares B; Aguado-Barrera ME; Parker C; Veldeman L; Fonteyne V; Bultijnck R; Talbot CJ; Symonds RP; Johnson K; Rattay T; Webb A; Lambrecht M; de Ruysscher D; Vanneste B; Choudhury A; Elliott RM; Sperk E; Herskind C; Veldwijk MR; Rancati T; Avuzzi B; Valdagni R; Azria D; Farcy Jacquet MP; Chang-Claude J; et al. "Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer". Radiother Oncol. 2022; 168: 75-82.

2021
Singh DP; Aujla K; Nead M; Bylund K. "Radiologically occult lung cancer curatively treated with high-dose rate endobronchial brachytherapy". J Clin Imaging Sci. 2021; 11: 45.

2020
Ryan Wolf J; Gewandter JS; Bautista J; Heckler CE; Strasser J; Dyk P; Anderson T; Gross H; Speer T; Dolohanty L; Bylund K; Pentland AP; Morrow GR. "Utility of topical agents for radiation dermatitis and pain: a randomized clinical trial". Support Care Cancer. 2020; 28(7): 3303-3311.

Books & Chapters

2016
Chapter Title: 7-Benzylidine-7-Dehydronaltrexone
Book Title: Reference Module in Biomedical Sciences
Author List: Bylund DB; Bylund K
Published By: Elsevier 2016

2015
Chapter Title: Endometrial Cancer
Book Title: Reference Module in Biomedical Sciences
Author List: Bylund KC
Published By: Elsevier 2015

2015
Chapter Title: Testicular Cancer
Book Title: Reference Module in Biomedical Sciences
Author List: Bylund KC
Published By: Elsevier 2015

VIEW ALL PUBLICATIONS